Co-Authors
This is a "connection" page, showing publications co-authored by Mario Cazzola and Alessandro Rambaldi.
Connection Strength
0.415
-
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019 08; 8(9):4089-4092.
Score: 0.052
-
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018 09 21; 8(10):89.
Score: 0.049
-
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018 09; 103(9):e392-e394.
Score: 0.048
-
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018 02 01; 36(4):310-318.
Score: 0.047
-
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 10 12; 130(15):1768-1771.
Score: 0.046
-
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017 06 15; 129(24):3227-3236.
Score: 0.044
-
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. Br J Cancer. 2017 01; 116(3):335-343.
Score: 0.044
-
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017 Jan; 92(1):E5-E6.
Score: 0.044
-
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016 09; 91(9):918-22.
Score: 0.042